Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Esperion's ETC-1002 lowers LDL cholesterol in phase II trial

Jan. 14, 2013

Ultragenyx inlicenses triheptanoin from Baylor Research Institute

Jan. 14, 2013

Metabolex presents new GPBA receptor agonists

Jan. 14, 2013

FDA advisory committee recommends approval of canagliflozin

Jan. 11, 2013

Oramed submits IND application for phase II trial of oral insulin candidate

Jan. 11, 2013

SK Biopharmaceuticals divulges new 1-beta-HSD1 inhibitors

Jan. 11, 2013

Novel 11-beta-HSD1 inhibitor with potential for treating diabetes identified at Pfizer

Jan. 11, 2013

Bayer's Skyla approved by FDA to prevent pregnancy for up to 3 years

Jan. 10, 2013

Takeda launches Lotriga 2 g for the treatment of hyperlipidemia in Japan

Jan. 10, 2013

Krystexxa approved in E.U. for certain patients with chronic tophaceous gout

Jan. 9, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...